HELSINKI, June 16, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical-stage biotechnology company developing APAC, a first-in-class antiplatelet and anticoagulant therapy for treating thrombo-inflammatory diseases, today announced the close of a EUR 4.8 million (approx. USD 5.6 million) financing round to support its expansion into a new Phase 2 clinical programme in arteriovenous fistula (AVF) maturation failure in end stage kidney disease.

The financing was led by existing investors Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund, alongside continued support from Finnish investors including the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation.

Aki Prihti, CEO at Aplagon, said, "This financing represents another important milestone for Aplagon as we continue to build momentum around APAC and its potential across a broad range of serious thrombo-inflammatory diseases. The financing supports the expansion of our clinical development plans in Phase 2 in Europe for AVF, having recently filed our CTA with the EMA. The continued backing from our experienced healthcare investors validates both the strength of our clinical progress and the growing recognition of APAC's differentiated mechanism of action that overcomes the limits of current treatments."

Johanna Asklin, General Partner at FSG, said, "Aplagon is addressing a major unmet need in thrombo-inflammatory disease with a highly differentiated therapeutic approach that has the potential to transform outcomes across several vascular indications. Since our initial investment, the company has continued to execute ...